Breast Cancer Clinical Trials in Irving, Texas

6 studies are recruiting for breast cancer in Irving, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

   This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A will test in…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Dallas, Irving, Texas

   Locations

   5 in total

   Run by

   Immunome, Inc.

   See if you can join NCT07578571 on ClinicalTrials.gov

2. Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

   This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts: * Part 1A is a dose escalation of STRO-006 monotherapy in selected tumor types reported to commonly express ITGB6. Part 1A will determine the safety, tolerability, pharmacokinetics (PK), and preliminar…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology Dallas, Irving, Texas

   Locations

   6 in total

   Run by

   Sutro Biopharma, Inc.

   See if you can join NCT07807345 on ClinicalTrials.gov

3. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

   The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   US Oncology Investigation Products Center(IPC), Irving, Texas

   Locations

   433 in total

   Run by

   Pfizer

   See if you can join NCT07062965 on ClinicalTrials.gov

4. A Study of PHST001 in Advanced Solid Tumors

   This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advan…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology - Dallas, Irving, Texas

   Locations

   20 in total

   Run by

   Pheast Therapeutics

   See if you can join NCT06840886 on ClinicalTrials.gov

5. A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology - Irving, Irving, Texas

   Locations

   65 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06618287 on ClinicalTrials.gov

6. Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

   This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT, Dallas, Irving, Texas

   Locations

   7 in total

   Run by

   MBrace Therapeutics

   See if you can join NCT07145255 on ClinicalTrials.gov